CL2014001529A1 - Compuestos pirazolo[1,5-a]piridina suistituidos, inhibidores del receptor de tropomiosina quinasa (trk); composicion farmaceutica que los comprende; metodo de inhibicion del recetor de tropomiosina quinasa a (trka); y metodo de tratamiento o prevencion del dolor, cancer, restenosis y aterosclerosis, entre otras enfermedades. - Google Patents

Compuestos pirazolo[1,5-a]piridina suistituidos, inhibidores del receptor de tropomiosina quinasa (trk); composicion farmaceutica que los comprende; metodo de inhibicion del recetor de tropomiosina quinasa a (trka); y metodo de tratamiento o prevencion del dolor, cancer, restenosis y aterosclerosis, entre otras enfermedades.

Info

Publication number
CL2014001529A1
CL2014001529A1 CL2014001529A CL2014001529A CL2014001529A1 CL 2014001529 A1 CL2014001529 A1 CL 2014001529A1 CL 2014001529 A CL2014001529 A CL 2014001529A CL 2014001529 A CL2014001529 A CL 2014001529A CL 2014001529 A1 CL2014001529 A1 CL 2014001529A1
Authority
CL
Chile
Prior art keywords
kinase receptor
tropomyosin kinase
trka
trk
restenosis
Prior art date
Application number
CL2014001529A
Other languages
English (en)
Inventor
Pradip Kumar Sasmal
Shahabat Ahmed
Ashok Tehim
Prasanna M Dattatreya
Nanjegowda Jagadeesh Mavinahalli
Vidyadhar Paradkar
Original Assignee
Reddys Lab Ltd Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddys Lab Ltd Dr filed Critical Reddys Lab Ltd Dr
Publication of CL2014001529A1 publication Critical patent/CL2014001529A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2014001529A 2011-12-12 2014-06-11 Compuestos pirazolo[1,5-a]piridina suistituidos, inhibidores del receptor de tropomiosina quinasa (trk); composicion farmaceutica que los comprende; metodo de inhibicion del recetor de tropomiosina quinasa a (trka); y metodo de tratamiento o prevencion del dolor, cancer, restenosis y aterosclerosis, entre otras enfermedades. CL2014001529A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN4329CH2011 2011-12-12

Publications (1)

Publication Number Publication Date
CL2014001529A1 true CL2014001529A1 (es) 2015-06-26

Family

ID=47902312

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001529A CL2014001529A1 (es) 2011-12-12 2014-06-11 Compuestos pirazolo[1,5-a]piridina suistituidos, inhibidores del receptor de tropomiosina quinasa (trk); composicion farmaceutica que los comprende; metodo de inhibicion del recetor de tropomiosina quinasa a (trka); y metodo de tratamiento o prevencion del dolor, cancer, restenosis y aterosclerosis, entre otras enfermedades.

Country Status (16)

Country Link
US (7) US9045479B2 (es)
EP (2) EP2791139B1 (es)
JP (1) JP5990595B2 (es)
KR (2) KR20140105508A (es)
CN (1) CN104114553B (es)
AU (1) AU2012351748B2 (es)
BR (1) BR112014014276A2 (es)
CA (1) CA2858958C (es)
CL (1) CL2014001529A1 (es)
CO (1) CO7071124A2 (es)
DK (1) DK2791138T3 (es)
EA (1) EA025352B1 (es)
ES (1) ES2686501T3 (es)
IL (1) IL233067B (es)
MX (1) MX356401B (es)
WO (2) WO2013088256A1 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
NZ604708A (en) 2010-05-20 2015-05-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
KR20140105508A (ko) * 2011-12-12 2014-09-01 닥터 레디스 레보러터리즈 리미티드 트로포미오신 수용체 키나제(Trk) 억제제인 치환된 피라졸로[1,5-a]피리딘
US9067914B1 (en) 2013-12-10 2015-06-30 Genzyme Corporation Tropomyosin-related kinase (TRK) inhibitors
US20170305857A1 (en) 2013-12-20 2017-10-26 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
CN103819343B (zh) * 2014-02-17 2016-03-23 青岛农业大学 化合物2-烯丙基-4-氟-6-硝基苯酚的制备方法和农用生物活性
WO2015143652A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
US20170197939A1 (en) 2014-04-15 2017-07-13 Pfizer Inc. Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
WO2015169776A1 (en) * 2014-05-08 2015-11-12 Bayer Cropscience Ag Pyrazolopyridine sulfonamides as nematicides
EP3157921A1 (en) 2014-06-23 2017-04-26 Dr. Reddy's Laboratories Ltd. Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
HUE061448T2 (hu) 2014-11-16 2023-07-28 Array Biopharma Inc (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid-hidrogénszulfát kristályos formája
TWI696621B (zh) 2014-12-18 2020-06-21 美商健臻公司 原肌球蛋白相關激酶（ｔｒｋ）抑制劑之醫藥調配物
CN104672121B (zh) * 2015-02-16 2017-10-24 上海华默西医药科技有限公司 2r‑(2,5‑二氟苯基)吡咯烷盐酸盐的制备方法
ES2822748T3 (es) * 2015-05-29 2021-05-04 Wuxi Fortune Pharmaceutical Co Ltd Inhibidor de cinasa Janus
CN108697708A (zh) 2015-10-26 2018-10-23 洛克索肿瘤学股份有限公司 Trk抑制剂抗性癌症中的点突变以及与此相关的方法
ES2987474T3 (es) 2016-04-04 2024-11-15 Loxo Oncology Inc Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
ES2836222T3 (es) 2016-05-18 2021-06-24 Loxo Oncology Inc Preparación de (S)-N-(5-((R)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
AU2017348826B2 (en) 2016-10-28 2021-12-02 Centaurus Biopharma Co., Ltd. Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN110869017B (zh) 2017-05-12 2023-05-05 英安塔制药有限公司 细胞凋亡信号调节激酶1抑制剂及其使用方法
US10253018B2 (en) 2017-05-25 2019-04-09 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218051A1 (en) 2017-05-25 2018-11-29 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218044A2 (en) 2017-05-25 2018-11-29 Enanta Pharmaceuticals Inc Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10800760B2 (en) 2017-05-31 2020-10-13 Nantbio, Inc. Trk inhibition
US10738033B2 (en) 2017-05-31 2020-08-11 Nantbio, Inc. Trk inhibition
CN107286070B (zh) * 2017-07-19 2019-07-16 浙江师范大学 (r)-2-(2,5-二氟苯基)吡咯烷的合成方法及中间体
WO2019046186A1 (en) 2017-08-28 2019-03-07 Enanta Pharmaceuticals, Inc. INHIBITORS OF KINASE 1 REGULATING THE APOPTOTIC SIGNAL CONTAINING TETRAZOLES AND METHODS OF USE THEREOF
US20190247398A1 (en) 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
CN109867672B (zh) * 2017-12-02 2020-07-07 广东东阳光药业有限公司 吡唑[1,5-a]吡啶衍生物的盐及其用途
CN109867668B (zh) * 2017-12-02 2021-03-26 广东东阳光药业有限公司 一种吡唑[1,5-a]吡啶化合物的晶型及其药物组合物和用途
CN109867671B (zh) * 2017-12-02 2020-07-07 广东东阳光药业有限公司 一种吡唑[1,5-a]吡啶化合物的晶型及其药物组合物和用途
US11179376B2 (en) * 2017-12-20 2021-11-23 Sunshine Lake Pharma Co., Ltd. Salts of pyrazolo[1,5-a]pyridine derivative and use thereof
CN108218754B (zh) * 2018-01-23 2021-05-07 广东赛烽医药科技有限公司 一种2-(2,5-二氟苯基)吡咯烷的制备方法
CA3090376A1 (en) 2018-02-06 2019-08-15 University Of Miami Inhibitors of the notch transcriptional activation complex kinase ("nack") and methods for use of the same
EP3773725A1 (en) 2018-03-29 2021-02-17 Loxo Oncology Inc. Treatment of trk-associated cancers
EP3787621B1 (en) 2018-05-02 2024-12-18 Enanta Pharmaceuticals, Inc. Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2019213239A1 (en) 2018-05-02 2019-11-07 Enanta Pharmaceuticals Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
GB201811825D0 (en) 2018-07-19 2018-09-05 Benevolentai Bio Ltd Organic compounds
CN108794370A (zh) * 2018-07-31 2018-11-13 上海弈柯莱生物医药科技有限公司 一种拉罗替尼中间体的制备方法
US10968199B2 (en) 2018-08-22 2021-04-06 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
GB201813791D0 (en) 2018-08-23 2018-10-10 Benevolental Bio Ltd Organic compounds
CN111171019A (zh) * 2018-11-13 2020-05-19 上海轶诺药业有限公司 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
WO2020106707A1 (en) 2018-11-19 2020-05-28 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN109593802B (zh) * 2018-12-24 2021-10-01 上海健康医学院 一种(r)-2-(2,5-二氟苯基)吡咯烷或其盐的制备方法
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US11466033B2 (en) 2019-03-25 2022-10-11 Enanta Pharmaceuticals, Inc. Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors
CN110015980A (zh) * 2019-05-14 2019-07-16 大连联化化学有限公司 一种合成叔丁基亚磺酰胺的方法
US12351590B2 (en) 2019-06-05 2025-07-08 Guangzhou Joyo Pharmatech Co., Ltd. Pyrrolopyrimidine compound and use thereof
CN110751853B (zh) * 2019-10-25 2021-05-18 百度在线网络技术（北京）有限公司 停车位数据的有效性识别方法和装置
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
US20230399319A1 (en) * 2019-12-27 2023-12-14 Japan Tobacco Inc. Acylsulfamide Compound and Pharmaceutical Use Therefor
WO2021148807A1 (en) 2020-01-22 2021-07-29 Benevolentai Bio Limited Pharmaceutical compositions and their uses
CN115297863A (zh) 2020-01-22 2022-11-04 博善人工智能生物科技有限公司 包含咪唑并[1,2-b]哒嗪化合物的表面药物组合物
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR102874188B1 (ko) * 2020-05-15 2025-10-21 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 융합된 아자 헤테로 시클릭 아미드계 화합물 및 이의 용도
EP4188918A1 (en) * 2020-07-29 2023-06-07 Ideaya Biosciences, Inc. Cyclized acetamido derivatives as dna polymerase theta inhibitors
CN112979646B (zh) * 2021-03-08 2022-01-14 北京富龙康泰生物技术有限公司 一种咪唑并吡啶类衍生物
WO2022234287A1 (en) 2021-05-06 2022-11-10 Benevolentai Bio Limited Imidazopyridazine derivatives useful as trk inhibitors
CN116115618B (zh) * 2021-11-15 2025-07-08 石药集团中奇制药技术（石家庄）有限公司 一种治疗肿瘤的药物
WO2023083356A1 (zh) * 2021-11-15 2023-05-19 石药集团中奇制药技术（石家庄）有限公司 固体形式的氮杂稠环酰胺类化合物及其用途
CN115772170B (zh) * 2021-12-03 2025-05-16 徐诺药业(南京)有限公司 一种吡唑并[1,5-a]吡啶衍生物及其制备方法和应用
JP2025540958A (ja) * 2022-11-30 2025-12-17 ブループリント メディシンズ コーポレイション 蕁麻疹の治療のための野生型ｃ－ｋｉｔキナーゼ阻害剤としてのＮ－フェニル－ピラゾロ［１，５－Ａ］ピリジン－３－カルボキサミド誘導体
WO2024123966A1 (en) * 2022-12-07 2024-06-13 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050364A1 (en) * 1997-05-03 1998-11-12 Smithkline Beecham Plc Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
US7196111B2 (en) * 2002-06-04 2007-03-27 Schering Corporation Pyrazolo[1,5a]pyrimidine compounds as antiviral agents
EP1527071A1 (en) 2002-07-25 2005-05-04 Pfizer Products Inc. Isothiazole derivatives useful as anticancer agents
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2006322187A1 (en) * 2005-12-08 2007-06-14 Novartis Ag Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors
AU2008273050A1 (en) 2007-07-11 2009-01-15 Auckland Uniservices Limited Pyrazolo[1,5-a]pyridines and their use in cancer therapy
WO2009140128A2 (en) 2008-05-13 2009-11-19 Irm Llc Compounds and compositions as kinase inhibitors
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
WO2012116217A1 (en) * 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
KR20140105508A (ko) * 2011-12-12 2014-09-01 닥터 레디스 레보러터리즈 리미티드 트로포미오신 수용체 키나제(Trk) 억제제인 치환된 피라졸로[1,5-a]피리딘

Also Published As

Publication number Publication date
EA201400701A1 (ru) 2014-11-28
EA025352B1 (ru) 2016-12-30
WO2013088256A1 (en) 2013-06-20
DK2791138T3 (en) 2018-09-17
US20150164869A1 (en) 2015-06-18
EP2791138A1 (en) 2014-10-22
CN104114553A (zh) 2014-10-22
CA2858958A1 (en) 2013-06-20
US9045478B2 (en) 2015-06-02
ES2686501T3 (es) 2018-10-18
EP2791139A1 (en) 2014-10-22
KR20140105508A (ko) 2014-09-01
JP5990595B2 (ja) 2016-09-14
US20170267677A1 (en) 2017-09-21
US9289419B2 (en) 2016-03-22
WO2013088257A1 (en) 2013-06-20
US10344031B2 (en) 2019-07-09
AU2012351748A1 (en) 2014-07-17
US20140371217A1 (en) 2014-12-18
IL233067A0 (en) 2014-07-31
MX2014006980A (es) 2015-04-08
KR20170005894A (ko) 2017-01-16
BR112014014276A2 (pt) 2017-06-13
CO7071124A2 (es) 2014-09-30
AU2012351748B2 (en) 2016-04-14
EP2791138B1 (en) 2018-06-06
US10047087B2 (en) 2018-08-14
KR101849143B1 (ko) 2018-04-16
EP2791139B1 (en) 2017-11-08
IL233067B (en) 2018-03-29
US9670207B2 (en) 2017-06-06
US20160264572A1 (en) 2016-09-15
CA2858958C (en) 2016-10-04
US20150005280A1 (en) 2015-01-01
CN104114553B (zh) 2017-03-01
US9402833B2 (en) 2016-08-02
US20150258076A1 (en) 2015-09-17
US9045479B2 (en) 2015-06-02
US20180354951A1 (en) 2018-12-13
MX356401B (es) 2018-05-21
NZ626306A (en) 2015-05-29
JP2015500275A (ja) 2015-01-05

Similar Documents

Publication Publication Date Title
CL2014001529A1 (es) Compuestos pirazolo[1,5-a]piridina suistituidos, inhibidores del receptor de tropomiosina quinasa (trk); composicion farmaceutica que los comprende; metodo de inhibicion del recetor de tropomiosina quinasa a (trka); y metodo de tratamiento o prevencion del dolor, cancer, restenosis y aterosclerosis, entre otras enfermedades.
UY37926A (es) Formulaciones de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo
CL2019000941A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
WO2016142855A3 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
MX388140B (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
CL2014001103A1 (es) Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros.
CL2009001212A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de cinasas; composicion farmaceutica que los comprende; y su uso en el tratamiento de demencia vascular, trastorno del snc, cancer, entre otras.
ZA201800022B (en) Substituted heterocyclyl derivatives as cdk inhibitors
DK3416964T3 (da) 6-Oxo-N-(1-(benzyl)-1H-pyrazol-4-YL)-6,7,8,9-tetrahydropyrido[3',2':4,5]pyrrolo[1,2-A]pyrazin-2-carboxamid-derivater som P90 ribosomal S6 kinase- (RSK-) hæmmere til behandling af cancer
HK1211942A1 (en) Pyrazolopyrimidine compounds as kinase inhibitors
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
MX377305B (es) DERIVADOS DE IMIDAZO[4,5-c]QUINOLINA E IMIDAZO[4,5-c][1,5]NAFTIRIDINA NOVEDOSOS COMO INHIBIDORES DE LRRK2.
PH12013501758A1 (en) Pyrazolo [1,5-a] pyridines as trk inhibitors
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
CL2014002518A1 (es) Compuestos derivados heterociclicos nitrogenados, inhibidores de la bace-1 o de la bace-2; composicion farmaceutica que los comprende; combinacion farmaceutica; su uso en el tratamiento o prevencion de la enfermedad de alzheimer o un deterioro cognitivo leve.
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
CL2011003082A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa.
MX2016009013A (es) Derivados de heterociclilo biciclicos como inhibores de cinasa-4 asociada al receptor de interleucina-1 (irak4).
CL2013002177A1 (es) Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos.
NI201000003A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
MX2016005394A (es) Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4.
NI201000004A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
IL211825A (en) Compounds based on pyridine and pyrimidine for use as wnt signal transducer inhibitors, pharmaceutical formulations containing such compounds and used as drugs for the treatment and / or cancer prevention
WO2011149950A3 (en) Bicyclic heteroaryl kinase inhibitors and methods of use
CL2013002063A1 (es) Compuestos derivados de pirrolo(piridina, pirimidina o pirazina), inhibidores de serina/trionina cinasa; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer, infecciones inflamaciones y enfermedades autoinmune.